XBiotech (XBIT) Stock Price, News & Analysis

Company Overview

XBiotech Inc. is a biotechnology company focused on developing therapies that target inflammation and other disease processes. The company’s technology platform is based on “True Human” monoclonal antibodies, which are derived from naturally occurring human antibodies rather than genetically engineered or animal-derived antibody sequences.

XBiotech’s research has included bermekimab, a fully human antibody designed to neutralize interleukin-1 alpha, an inflammatory protein associated with cancer, autoimmune conditions and other diseases. The company has evaluated bermekimab in clinical studies involving cancer and inflammatory disorders, while continuing to research additional antibody-based treatments and potential applications.

Founded in 2005 and headquartered in Austin, Texas, XBiotech has pursued the discovery, development and potential commercialization of biological therapies for patients in the United States and international markets. John Simard, the company’s founder, has served as its chairman and chief executive officer.

Key Stats

• Today's Range: $2.19 to $2.20
• 50-Day Range: $2.15 to $2.46
• 52-Week Range: $2.09 to $3.44
• Volume: 25,235 shs
• Average Volume: 33,518 shs
• Market Capitalization: $66.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

XBiotech Stock Analysis - MarketRank™

XBiotech scored higher than 17% of companies evaluated by MarketBeat, and ranked 812th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

XBiotech has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

XBiotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of XBiotech is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of XBiotech is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

XBiotech has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.65% of the float of XBiotech has been sold short.

Short Interest Ratio / Days to Cover

XBiotech has a short interest ratio ("days to cover") of 4.97.

Change versus previous month

Short interest in XBiotech has recently increased by 1.25%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

XBiotech does not currently pay a dividend.

Dividend Growth

XBiotech does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

XBiotech has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for XBiotech this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for XBIT on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, XBiotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.80% of the stock of XBiotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

55.70% of the stock of XBiotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XBIT
• CIK: 1626878
• Web: www.xbiotech.com
• Phone: (512) 386-2900
• Fax: 512-386-5505
• Employees: 87
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): ($1.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.54 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -31.62%
• Return on Assets: -30.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 33.15
• Quick Ratio: 33.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.60 per share
• Price / Book: 0.48

Miscellaneous

• Outstanding Shares: 30,490,000
• Free Float: 21,098,000
• Market Cap: $66.77 million
• Optionable: Optionable
• Beta: 0.79